The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes

Transplant International

Volumn 27, Issue 10, 2014, Pages 1029-1038

  Banasik, Mirosław ^a   Boratyńska, Maria ^a   Kos̈cielska Kasprzak, Katarzyna ^a   Kamińska, Dorota ^a   Bartoszek, Dorota ^a   Zabińska, Marcelina ^a   Myszka, Marta ^a   Zmonarski, Sławomir ^a   Protasiewicz, Marcin ^a   Nowakowska, Beata ^b   Hałoń, Agnieszka ^a   Chudoba, Pawel ^a   Klinger, Marian ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

angiotensin II type 1 receptor antibodies; antibody mediated rejection; humoral rejection; non HLA antibodies; renal transplant injury; renal transplantation

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; BASILIXIMAB; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONHLA ANTIBODY; PROTEIN ANTIBODY; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; AUTOANTIBODY; BIOLOGICAL MARKER; HLA ANTIGEN;

ANTIBODY MEDIATED REJECTION; ARTICLE; GRAFT FAILURE; GRAFT RECIPIENT; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; ADULT; ADVERSE EFFECTS; COHORT ANALYSIS; CONFIDENCE INTERVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT REJECTION; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PREOPERATIVE CARE; PROCEDURES; RISK; SENSITIVITY AND SPECIFICITY;

ADULT; AUTOANTIBODIES; BIOLOGICAL MARKERS; COHORT STUDIES; CONFIDENCE INTERVALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; ODDS RATIO; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RECEPTOR, ANGIOTENSIN, TYPE 1; SENSITIVITY AND SPECIFICITY; TRANSPLANTATION IMMUNOLOGY;

EID: 84925635554     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12371     Document Type: Article

References (49)

1. Dragun D, Brasen JH, Schonemann C, et al,. Patients with steroid refractory acute vascular rejection develop agonistic antibodies targeting angiotensin II type 1 receptor. Transpl Proc 2003; 35: 2104.
2. Dragun D, Muller DN, Brasen JH, et al,. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352: 558.
3. Banasik M, Boratynska M, Koscielska-Kasprzak K, et al,. The impact of non-HLA antibodies directed against Endothelin-1 type A receptors (ETAR) on early renal transplant outcomes. Transpl Immunol 2013; 30: 24.
4. Banasik M, Boratynska M, Koscielska-Kasprzak K, et al,. Long-term follow-up of non-HLA and anti-HLA antibodies: incidence and importance in renal transplantation. Transpl Proc 2013; 45: 1462.
5. Hiemann NE, Meyer R, Wellnhofer E, et al,. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation 2012; 94: 919.
6. Giral M, Foucher Y, Dufay A, et al,. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am J Transplant 2013; 13: 2567.
7. Taniguchi M, Rebellato LM, Cai J, et al,. Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies. Am J Transplant 2013; 13: 2577.
8. Dzau VJ,. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001; 37: 1047.
9. Dragun D, Catar R, Philippe A,. Non-HLA antibodies in solid organ transplantation: recent concepts and clinical relevance. Curr Opin Organ Transplant 2013; 18: 430.
10. Reinsmoen NL,. Role of angiotensin II type 1 receptor-activating antibodies in solid organ transplantation. Hum Immunol 2013; 74: 1474.
11. Nath DS, Basha HI, Mohanakumar T,. Antihuman leukocyte antigen antibody-induced autoimmunity: role in chronic rejection. Curr Opin Organ Transplant 2010; 15: 16.
12. Reinsmoen NL, Lai CH, Heidecke H, et al,. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 2010; 90: 1473.
13. Dragun D,. The role of angiotensin II type 1 receptor-activating antibodies in renal allograft vascular rejection. Pediatr Nephrol 2007; 22: 911.
14. Lebranchu Y, Baan C, Biancone L, et al,. Pre-transplant identification of acute rejection risk following kidney transplantation. Transpl Int 2013; 27: 129.
15. Heagerty PJ, Lumley T, Pepe MS,. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000; 56: 337.
16. Saha-Chaudhuri P, Heagerty PJ,. Non-parametric estimation of a time-dependent predictive accuracy curve. Biostatistics 2013; 14: 42.
17. Yin J, Tian L,. Optimal linear combinations of multiple diagnostic biomarkers based on Youden index. Stat Med 2014; 33: 1426.
18. Hothorn T, Zeileis A,. Generalized maximally selected statistics. Biometrics 2008; 64: 1263.
19. Cai J, Qing X, Tan J, et al,. Humoral theory of transplantation: some hot topics. Br Med Bull 2013; 105: 139.
20. Terasaki PI,. A personal perspective: 100-year history of the humoral theory of transplantation. Transplantation 2012; 93: 751.
21. Wekerle T,. Taming the ABO barrier in transplantation. Blood 2013; 122: 2527.
22. Hirai T, Kohei N, Omoto K, et al,. Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection. Transpl Int 2012; 25: 925.
23. Legendre C, Canaud G, Martinez F,. Factors influencing long-term outcome after kidney transplantation. Transpl Int 2013; 27: 19.
24. Banasik M, Boratynska M, Koscielska-Kasprzak K, et al,. The impact of de novo donor-specific anti-human leukocyte antigen antibodies on 5-year renal transplant outcome. Transpl Proc 2013; 45: 1449.
25. Bartel G, Wahrmann M, Schwaiger E, et al,. Solid phase detection of C4d-fixing HLA antibodies to predict rejection in high immunological risk kidney transplant recipients. Transpl Int 2013; 26: 121.
26. Crespo M, Torio A, Mas V, et al,. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? Transpl Immunol 2013; 29: 28.
27. Billing H, Sander A, Susal C, et al,. Soluble CD30 and ELISA-detected human leukocyte antigen antibodies for the prediction of acute rejection in pediatric renal transplant recipients. Transpl Int 2013; 26: 331.
28. Schaier M, Seissler N, Becker LE, et al,. The extent of HLA-DR expression on HLA-DR(+) Tregs allows the identification of patients with clinically relevant borderline rejection. Transpl Int 2013; 26: 290.
29. Bilalic S, Veitinger M, Ahrer KH, et al,. Identification of Non-HLA antigens targeted by alloreactive antibodies in patients undergoing chronic hemodialysis. J Proteome Res 2010; 9: 1041.
30. Martin L, Guignier F, Mousson C, et al,. Detection of donor-specific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy. Transplantation 2003; 76: 395.
31. Haas M, Sis B, Racusen LC, et al,. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14: 272.
32. Buob D, Grimbert P, Glowacki F, et al,. Three-year outcome of isolated glomerulitis on 3-month protocol biopsies of donor HLA antibody negative patients. Transpl Int 2012; 25: 663.
33. Lefaucheur C, Loupy A, Vernerey D, et al,. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet 2013; 381: 313.
34. Dragun D, Philippe A, Catar R, et al,. Autoimmune mediated G-protein receptor activation in cardiovascular and renal pathologies. Thromb Haemost 2009; 101: 643.
35. Dragun D, Hegner B,. Non-HLA antibodies post-transplantation: clinical relevance and treatment in solid organ transplantation. Contrib Nephrol 2009; 162: 129.
36. Kaminska D, Tyran B, Mazanowska O, et al,. Cytokine gene expression in kidney allograft biopsies after donor brain death and ischemia-reperfusion injury using in situ reverse-transcription polymerase chain reaction analysis. Transplantation 2007; 84: 1118.
37. Irani RA, Zhang Y, Blackwell SC, et al,. The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia. J Exp Med 2009; 206: 2809.
38. Riemekasten G, Philippe A, Nather M, et al,. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2011; 70: 530.
39. Win TS, Pettigrew GJ,. Humoral autoimmunity and transplant vasculopathy: when allo is not enough. Transplantation 2010; 90: 113.
40. Dragun D, Philippe A, Catar R,. Role of non-HLA antibodies in organ transplantation. Curr Opin Organ Transplant 2012; 17: 440.
41. Legendre C, Canaud G, Martinez F,. Factors influencing long-term outcome after kidney transplantation. Transpl Int 2014; 27: 19.
42. Tait BD, Susal C, Gebel HM, et al,. Consensus guidelines on the testing and clinical management issues associated with HLA and Non-HLA antibodies in transplantation. Transplantation 2013; 95: 19.
43. Banasik M, Boratynska M, Nowakowska B, et al,. C4D deposition and positive posttransplant crossmatch are not necessarily markers of antibody-mediated rejection in renal allograft recipients. Transpl Proc 2007; 39: 2718.
44. Chaudhuri A, Ozawa M, Everly MJ, et al,. The clinical impact of humoral immunity in pediatric renal transplantation. J Am Soc Nephrol 2013; 24: 655.
45. Banasik M, Boratynska M, Nowakowska B, et al,. Variability in donor-specific alloantibody production after transplantation. Transpl Proc 2007; 39: 2715.
46. Everly MJ, Rebellato LM, Haisch CE, et al,. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013; 95: 410.
47. Roelen DL, Doxiadis II, Claas FH,. Detection and clinical relevance of donor specific HLA antibodies: a matter of debate. Transpl Int 2012; 25: 604.
48. Banasik M, Boratynska M, Kooecielska-Kasprzak K, et al,. Non-HLA antibodies: anti-AT1R and anti-ETAR are associated with renal allograft injury and graft loss. Transpl Int 2013; 26: 77.
49. Billing H, Rieger S, Susal C, et al,. IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up. Transpl Int 2012; 25: 1165.